These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33136464)

  • 1. Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy.
    G Lahori D; Varamini P
    Future Oncol; 2021 Feb; 17(6):711-722. PubMed ID: 33136464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotherapeutics for Antimetastatic Treatment.
    Yang F; Zhao Z; Sun B; Chen Q; Sun J; He Z; Luo C
    Trends Cancer; 2020 Aug; 6(8):645-659. PubMed ID: 32448754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral adjuvant therapy for colorectal cancer: recent developments and future targets.
    Shahiwala A; Qawoogha SS; Tambuwala MM
    Ther Deliv; 2019 Oct; 10(10):659-669. PubMed ID: 31702443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy combinations for the treatment of patients with solid tumors.
    Bluthgen MV; Basté N; Recondo G
    Future Oncol; 2020 Aug; 16(23):1715-1736. PubMed ID: 32501724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options.
    Le Calvez B; Moreau P; Touzeau C
    Expert Opin Investig Drugs; 2021 Sep; 30(9):965-973. PubMed ID: 34253136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.
    Gorbet MJ; Ranjan A
    Pharmacol Ther; 2020 Mar; 207():107456. PubMed ID: 31863820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.
    Zhang F; Stephan SB; Ene CI; Smith TT; Holland EC; Stephan MT
    Cancer Res; 2018 Jul; 78(13):3718-3730. PubMed ID: 29760047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
    Deng H; Zhang Z
    J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential and Timely Combination of a Cancer Nanovaccine with Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse.
    Kim Y; Kang S; Shin H; Kim T; Yu B; Kim J; Yoo D; Jon S
    Angew Chem Int Ed Engl; 2020 Aug; 59(34):14628-14638. PubMed ID: 32430981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleic Acid Aptamers as Emerging Tools for Diagnostics and Theranostics.
    Mutreja R; Baba SA; Navani NK
    Methods Mol Biol; 2019; 2054():201-221. PubMed ID: 31482458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
    Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
    ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials.
    Yadav D; Kwak M; Chauhan PS; Puranik N; Lee PCW; Jin JO
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):909-922. PubMed ID: 35181474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future.
    Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2018 Jul; 27(7):569-572. PubMed ID: 29958097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.